Binnopharm Group

Name

Binnopharm Group

Legal name

OOO «Биннофарм Групп»

Website

https://binnopharmgroup.ru

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Generic Hospital & Institutional Products (HLAIABAL), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• Biotechnology drugs
• Active pharmaceutical ingredients
• Medical devices

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription and over-the-counter pharmaceutical products across hospital/tender and retail pharmacy segments in Russia and export markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

Binnopharm Group is one of Russia's largest pharmaceutical manufacturers, producing a diversified portfolio of more than 600 registered prescription and OTC drugs, vaccines, biotechnological preparations, and medical aesthetic devices. Operating six production sites across Russia with a combined area of over 700,000 m², the company manufactures both active pharmaceutical substances (APIs) and finished dosage forms spanning 20+ dosage forms including tablets, capsules, powders, gels, ointments, sprays, injections, and suppositories.

Product overview

Binnopharm Group is a Russian pharmaceutical company that operates as a unified platform combining six manufacturing sites (Synthes, ALIUM, Binnopharm, Biocom, NIARMEDIK PHARMA, and BioPHARMAHOLDING). The company produces a diversified portfolio of prescription and OTC drugs exceeding 600 registration certificates, spanning therapeutic areas including antibiotics, cardiovascular drugs, neurological medications, gastroenterology products, vaccines, and biotechnological preparations. The product portfolio includes branded products under the AKOS sub-brand, generic medications, dietary supplements, and medical devices for aesthetic medicine. Manufacturing capabilities cover over 20 dosage forms including tablets, capsules, powders, gels, ointments, sprays, injections, and suppositories. The company also operates an R&D center launched in 2023 for pharmaceutical development of chemical synthesis and biotechnological drugs.

Differentiator

Problem solved

Functional benefit

Brands

• АКОС: Sub-brand for OTC and generic pharmaceuticals (e.g., Амлодипин-АКОС, Ибупрофен-АКОС, Диклофенак-АКОС, Гентамицин-АКОС, Цефазолин-АКОС, Сульфотаксим-АКОС, and many others).
• Регевак
• Кагоцел
• Коллост (COLLOST)
• Кипферон

Products and services

• Heparin (Гепарин) Anticoagulant drug for injection, used for prevention and treatment of venous thromboses, pulmonary artery thromboembolism, and arterial embolisms.
• Kipferon® (Кипферон) Immunoglobulin preparation with interferon alfa-2b for treatment of secondary immunodeficiencies, acute respiratory diseases, and intestinal infections.
• Kagocel® (Кагоцел) Antiviral drug for prevention and treatment of influenza and ARVI in adults and children from 3 years, also for herpes treatment in adults.
• Regevac B® (Регевак В) Recombinant hepatitis B vaccine for specific prevention of viral hepatitis B caused by all known subtypes.
• Sputnik V (Гам-КОВИД-Вак) COVID-19 vaccine produced at the Binnopharm Zelenograd biopharmaceutical site.
• COLLOST® Collagen-based medical device for aesthetic medicine, a unique high-tech product based on type I collagen produced at the Mosalsk full-cycle production site.

Quantifiable outcome

• 36.9 billion rubles net revenue in 2025
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• R-Pharm: R-Pharm is a major Russian pharmaceutical company with vertically integrated manufacturing of original and generic drugs, biologics, and vaccines, including hospital and retail segments directly overlapping with Binnopharm's portfolio and channels.
• Pharmstandard: Pharmstandard is Russia's largest domestic pharmaceutical manufacturer, producing a comparable portfolio of prescription and OTC drugs across multiple therapeutic areas for both hospital and retail channels. It is Binnopharm's closest direct competitor on the Russian market.
• Valenta Pharm: Valenta Pharm is a Russian pharmaceutical company producing branded and OTC products across multiple therapeutic areas for the domestic market. Comparable as a Russian-domestic branded-generic manufacturer with retail and hospital exposure.
• Veropharm: Veropharm is a Russian generic and specialty pharmaceutical manufacturer producing tablets, ointments, suppositories, and injectables for hospital and retail markets. It competes head-to-head with Binnopharm across several dosage forms and therapeutic groups.

Emerging players

• BIOCAD: BIOCAD is one of Russia's largest biotechnology companies developing and manufacturing biosimilars, monoclonal antibodies, and innovative biologics. It is comparable to Binnopharm in biopharma ambition and competes for biotech talent and government biotech contracts.
• Generium: Generium is a leading Russian biopharmaceutical company specializing in recombinant biological products, biosimilars, and gene therapy - directly overlapping with Binnopharm's Zelenograd biotech operations and future R&D pipeline.

Regional players

• Polpharma: Polpharma is the largest Polish pharmaceutical manufacturer and a leading generic producer in CEE, with API and finished-dose capabilities. Comparable in generic pharma + API integration and regional market orientation.

Broad incumbents

• STADA Arzneimittel: STADA is a major European generic and consumer healthcare company with broad product portfolio across multiple dosage forms and CIS market presence. Comparable to Binnopharm in generic + OTC mix and multi-country distribution model.
• KRKA: KRKA is a leading Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished-dose production across CEE/CIS markets. Comparable in business model (generics + branded generics + API), geographic emphasis on CIS, and multi-site manufacturing structure.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with massive global production footprint spanning APIs, finished generics, and biosimilars. Comparable as a multi-site generic manufacturer with broad therapeutic and dosage-form coverage.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/binnopharm-group

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Binnopharm Group